Cytosorbents Corporation
CTSO
$1.10
-$0.03-2.66%
09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | 09/30/2023 | |
---|---|---|---|---|---|
Revenue | 1.80% | 2.17% | 3.50% | 4.79% | 2.75% |
Total Other Revenue | -- | -- | -- | -- | -- |
Total Revenue | 1.80% | 2.17% | 3.50% | 4.79% | 2.75% |
Cost of Revenue | -1.13% | -15.17% | -15.91% | 0.01% | 8.65% |
Gross Profit | 3.63% | 15.08% | 18.88% | 8.00% | -0.62% |
SG&A Expenses | -0.64% | 1.99% | 3.56% | 0.91% | -9.73% |
Depreciation & Amortization | -- | -- | -- | -- | -- |
Other Operating Expenses | -- | -- | -- | -- | -- |
Total Operating Expenses | -8.81% | -6.98% | -3.81% | 1.44% | -7.84% |
Operating Income | 22.98% | 18.21% | 12.08% | 2.29% | 19.00% |
Income Before Tax | 20.58% | 4.34% | 12.12% | 13.52% | 41.72% |
Income Tax Expenses | 25.53% | 25.53% | 25.53% | 25.53% | -48.45% |
Earnings from Continuing Operations | 20.35% | 3.47% | 11.65% | 13.12% | 43.32% |
Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
Minority Interest in Earnings | -- | -- | -- | -- | -- |
Net Income | 20.35% | 3.47% | 11.65% | 13.12% | 43.32% |
EBIT | 22.98% | 18.21% | 12.08% | 2.29% | 19.00% |
EBITDA | 25.17% | 20.68% | 14.68% | 4.27% | 20.75% |
EPS Basic | 32.05% | 13.04% | 17.53% | 15.04% | 43.96% |
Normalized Basic EPS | 33.43% | 15.80% | 19.10% | 16.58% | 42.68% |
EPS Diluted | 32.05% | 13.04% | 17.53% | 15.47% | 44.18% |
Normalized Diluted EPS | 33.43% | 15.80% | 19.10% | 16.58% | 42.68% |
Average Basic Shares Outstanding | 19.28% | 14.04% | 8.44% | 2.48% | 0.90% |
Average Diluted Shares Outstanding | 19.28% | 14.04% | 8.44% | 2.48% | 0.90% |
Dividend Per Share | -- | -- | -- | -- | -- |
Payout Ratio | -- | -- | -- | -- | -- |